Sugi Predict

Sugi Predict / Targets / GPER1

GPER1

G-protein coupled estrogen receptor 1 · Q99527 · GPER1 on Sugi Atlas →

5,799 patent compounds predicted against GPER1, 4,251 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL916391 SCHEMBL916391 1.00 3/20
SCHEMBL917688 SCHEMBL917688 0.79 3/20
SCHEMBL915340 SCHEMBL915340 0.76 3/20
SCHEMBL916163 SCHEMBL916163 0.75 3/20
SCHEMBL915286 SCHEMBL915286 0.73 3/20
SCHEMBL916774 SCHEMBL916774 0.71 3/20
SCHEMBL916446 SCHEMBL916446 0.68 3/20
SCHEMBL916386 SCHEMBL916386 0.65 3/20
SCHEMBL916068 SCHEMBL916068 0.62 3/20
SCHEMBL916308 SCHEMBL916308 0.60 3/20
SCHEMBL917263 SCHEMBL917263 0.57 3/20
SCHEMBL916034 SCHEMBL916034 0.56 3/20
SCHEMBL916392 SCHEMBL916392 0.54 3/20
SCHEMBL916305 SCHEMBL916305 0.52 3/20
SCHEMBL915699 SCHEMBL915699 0.52 3/20
SCHEMBL916384 SCHEMBL916384 0.51 3/20
SCHEMBL917713 SCHEMBL917713 0.48 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1889089) 0.39 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1889091) 0.39 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL1481567) 0.35 3/20

Clinical trials — most relevant to GPER1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? PHASE4COMPLETED
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
Raloxifene and Rimostil for Perimenopause-Related Depression PHASE4COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women PHASE3COMPLETED
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer PHASE3COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Estrogen Receptor Beta and Mood PHASE2COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women PHASE1COMPLETED
S-Equol in Alzheimer's Disease (SEAD) Trial PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Estrogen Receptors and Chronic Venous Disease nanCOMPLETED
Estrogens Levels and Receptors Status and Skin Tears nanUNKNOWN
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen nanUNKNOWN
Estrogen Receptors and Peripheral Artery Disease nanUNKNOWN
Sexual Hormones and Haemostasis: Observations for Women Health nanUNKNOWN
Aromatase Inhibitor Clinical Trial nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer nanCOMPLETED
Expression of Steroid Receptors in Endometrium nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer nanCOMPLETED
Menopause Effects on Vascular Function nanCOMPLETED
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus nanCOMPLETED
FES-PET for Patients Treated on NCI Protocol 8762 nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a GPER1 binder may also engage these)

ProteinNameSimilarity
F7EQ49 — 1.000 F7EQ49 →
Q8BMP4 — 0.996 Q8BMP4 →
O08878 — 0.995 O08878 →
B0F9W3 — 0.981 B0F9W3 →
B3G515 — 0.978 B3G515 →
Q8HZP3 — 0.967 Q8HZP3 →
Q95L01 — 0.966 Q95L01 →
Q3BCU0 — 0.965 Q3BCU0 →
Q8VIH9 — 0.964 Q8VIH9 →
Q28642 — 0.963 Q28642 →
Q8HZP2 — 0.963 Q8HZP2 →
BDKRB1 B1 bradykinin receptor 0.961 landscape →
Q8HZN9 — 0.961 Q8HZN9 →
Q9GLX8 — 0.961 Q9GLX8 →
P49220 — 0.960 P49220 →
Q8HZP1 — 0.960 Q8HZP1 →
Q8BUD0 — 0.960 Q8BUD0 →
GPR4 G-prodeshotein coupled receptor 4 0.960 landscape →
P49684 — 0.960 P49684 →
P25023 — 0.959 P25023 →
P50132 — 0.959 P50132 →
O88410 — 0.958 O88410 →
Q4KLH9 — 0.958 Q4KLH9 →
Q9JII9 — 0.957 Q9JII9 →
O46685 — 0.957 O46685 →
GPR68 G-protein coupled receptor 68 0.956 landscape →
A0T2N3 — 0.956 A0T2N3 →
Q5KSK8 — 0.956 Q5KSK8 →
Q9R0Q2 — 0.954 Q9R0Q2 →
O88855 — 0.954 O88855 →